NEW HAVEN, Connecticut and KORTRIJK, Belgium, February 19 /PRNewswire/ --
- Natural Supplement for Attention-Deficit Hyperactivity Disorder in Children Fulfills Growing Need Throughout Asia -
RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental(R) throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.